Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
The cost-effectiveness of ketamine therapy health economic evidence is promising for treatment-resistant depression, but the answer depends on the treatment route, maintenance needs, insurance coverage, and how long improvement lasts. Published modeling has generally found generic intravenous ketamine to have a lower cost per quality-adjusted life year than intranasal esketamine at list-price assumptions. Those results are not a guarantee of affordability for an individual patient, especially when IV treatment is paid out of pocket.
Treatment-resistant depression can involve repeated medication trials, ongoing functional impairment, and higher use of healthcare services. Before comparing options, review what a treatment course includes, what your plan covers, and how progress and maintenance treatment would be assessed.
Quick Answer
Economic models suggest IV racemic ketamine may provide better value than intranasal esketamine for treatment-resistant depression because generic ketamine has lower drug acquisition costs. Esketamine has an FDA-approved indication and an established insurance pathway, while IV ketamine for depression is commonly an off-label service with variable coverage. The best financial choice depends on the total treatment plan, not the medication price alone.
What cost-effectiveness means in ketamine care
Cost-effectiveness analysis compares added costs with added health benefit. A common measure is the quality-adjusted life year, or QALY, which combines length of life and health-related quality of life into one measure. An incremental cost-effectiveness ratio, or ICER, estimates the additional cost required for one additional QALY compared with another treatment strategy.
These analyses help payers and health systems compare options, but they do not determine a patient’s bill. A model may include medication, clinical visits, monitoring, and estimated outcomes over several years. It may not fully capture travel, time away from work, caregiver burden, or differences between local clinic prices.
According to the National Institute of Mental Health, major depression can substantially impair daily functioning, which is one reason economic analyses consider outcomes beyond prescription costs. See the NIMH depression overview for background on depressive disorders and treatment.
What published economic models found
A 2020 health-economic model by Ross and Soeteman compared IV ketamine, intranasal esketamine, and treatment as usual for treatment-resistant depression over five years. The model reported more favorable cost-effectiveness estimates for IV ketamine than for esketamine under its base-case assumptions, largely because of the difference in treatment costs. The comparison remains limited because direct head-to-head clinical evidence is limited and modeled results change when assumptions about response durability and maintenance frequency change.
The study’s estimates placed IV ketamine at roughly $36,000-$56,000 per QALY versus treatment as usual, depending on assumptions. Esketamine’s estimated ICER was higher, roughly $100,000-$200,000 per QALY at modeled list-price assumptions. Read the study record at PubMed for the methods and limitations.
These figures are model outputs, not quoted treatment prices or a clinical recommendation. They should be interpreted alongside safety, diagnosis, treatment history, access to monitoring, and the patient’s ability to continue care if maintenance treatment is needed.
Compare low-dose options
Review routes, dosing discussions, and alternatives before speaking with a clinician.
Compare optionsKey Takeaway
The lower medication cost of generic IV ketamine does not automatically mean lower out-of-pocket cost. Coverage, clinic fees, travel, required observation, and the number of maintenance treatments can change the real comparison.
The costs that can change the decision
For IV ketamine, the medication itself is only one part of the charge. Ask whether the quoted amount includes the evaluation, infusion supplies, nursing time, clinician oversight, monitoring, and recovery observation. Ask whether an induction series is recommended and how maintenance decisions are made. Our guide to how many ketamine treatments may be needed explains why treatment schedules vary.
For esketamine, the treatment center must follow the product’s required supervised-use process. Coverage may include prior authorization, documentation of previous treatment attempts, deductibles, coinsurance, or limits set by a plan. The manufacturer, insurer, and treating site can explain their current billing and assistance processes, but eligibility and patient costs are plan-specific.
Frequency is a major driver for either route. A short induction course and a longer maintenance plan are economically different decisions. Review how low-dose ketamine treatments may be spaced when discussing the practical implications of ongoing visits.
Potential value factors
- A rapid clinical response may reduce the need for additional ineffective treatment trials for some patients.
- Generic IV ketamine can have lower modeled treatment costs than branded esketamine.
- Established esketamine coverage pathways may reduce direct patient expense for some insured patients.
Important limitations
- A response cannot be predicted from an economic model.
- Maintenance frequency and response durability can substantially change total cost.
- IV ketamine coverage for depression varies because the use is generally off label.
- Indirect cost savings, such as fewer hospitalizations or improved work functioning, are difficult to prove for an individual patient.
Questions to ask before choosing a treatment option
Use a written estimate and compare the complete care pathway. This is especially important if you are weighing a covered option against an out-of-pocket clinic program.
Treatment cost checklist
- What does the quoted per-session amount include, including assessment, medication, monitoring, and recovery time?
- How many induction visits are proposed, and what would trigger maintenance treatment?
- Will the provider submit insurance claims or provide documentation for possible reimbursement?
- What prior authorization or treatment-history documentation does my insurer require?
- What costs will I have for transportation, time away from work, or a support person after treatment?
- How will the care team measure benefit and decide whether continuing treatment is justified?
Fit guidance and next steps
IV ketamine may be worth discussing for people with treatment-resistant depression who can access an appropriately monitored setting and understand the likely self-pay or reimbursement uncertainty. Esketamine may be a practical option for people whose clinician considers it appropriate and whose insurance offers usable coverage. Neither option is simply a lower-cost substitute for individualized clinical assessment.
Cost should not be separated from safety and treatment fit. Review common ketamine side effects and discuss your medication history, medical conditions, transportation plan, and follow-up care with a qualified clinician. For context on when depression may be considered treatment resistant, see next steps for treatment-resistant depression.
Learn More
Contact us to learn how to evaluate ketamine treatment information, expected care steps, and questions to bring to a clinician or insurer.
Frequently asked questions
Share
Related Reading
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.